Sangamo Q3 revenues up 99%; shares up 5% after hours

|About: Sangamo Therapeutics, ... (SGMO)|By:, SA News Editor

Sangamo Therapeutics (NASDAQ:SGMO) Q3 results ($M): Revenues: 23.5 (+99.2%), includes $9M in collaboration revenue from Kite Pharma.

Net loss: (12.8) (-3.2%); loss/share: (0.13) (+13.3%).

2018 guidance: Quick asset balance at year-end: at least $380M; operating expenses: $160M - 165M.

Previously: Sangamo Therapeutics beats by $0.02, misses on revenue (Nov. 8)

Subscribe for full text news in your inbox